Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03009500
Other study ID # 16-5927
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2017
Est. completion date June 2019

Study information

Verified date March 2020
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate three different injectable solutions used to block ankle nerves to manage ankle pain. The current standard of medical care is to inject a combination of local anesthetics and steroids around injured nerves. There is evidence that injection of local anesthetic (without the steroid) can calm the injured nerve and provide pain relief from a few days up to a few months. Injection of sterile salt water also has the potential to provide pain relief by breaking scar tissue around the nerve thereby relieving compression. Injections of local anesthetic and steroids around injured nerves have been used for many years to provide relief of pain but the specific reason is not well known for this benefit.

There are three possibilities: 1) Steroids can reduce inflammation and calm the nerves, 2) local anesthetics can have similar actions but with shorter duration (few days), and 3) injection of any solution can break scarring around an injured/compressed nerve.

The study will compare pain relief and possible adverse effects from these three different solutions. This study will help provide definitive answers regarding pain relief and possible adverse effects of the three solutions. This, in turn, will determine the best possible option for injection in patients with nerve-related injury pain.


Description:

This project is a randomized controlled trial with the aim of comparing efficacy of image (ultrasound)-guided administration of perineural combination of steroids and local anesthetic (current standard of care) against perineural local anesthetic (LA) or saline in providing sustained analgesic benefit in people with chronic neuropathic pain (NP) of the foot and ankle.

The study design will be multi-center, prospective, concealed, blinded, parallel group trial with three groups, block randomization (blocks of six participants) and allocation in a 2:2:2 ratio. Study participants and outcome evaluators will be blinded to treatment assignments.

Participants will be randomly assigned to one of the three groups to receive two US-guided injections (at an interval of one to two weeks) of one of the following around one or more of the five nerves innervating the foot and ankle:

The initial procedure will be repeated after one to two weeks unless clinical circumstances dictate otherwise (that is, the patient declined a second injection because of increase in pain or satisfaction with pain relief). The rationale for the repeat procedure is to allow possible benefit from a cumulative effect of the procedures and/or the injectates. Between the first injection and first follow-up visit, no patient will be allowed any additional therapeutic interventions. Nerves to be targeted by the injection will be decided by the treating physician based on area of the foot and ankle that displays features of neuropathic pain. Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of LA (2% lidocaine) at each of the injection sites. This will reduce discomfort of the study participants from the injections. The subcutaneous LA will also cause numbness of the skin and this will ensure blinding of participants to their group allocation. Two ultrasound-guided procedures will be performed at weekly intervals over two weeks. The US-guided technique for performing these procedures has been described in previous studies from our center.22 Conservative measures (oral analgesics, physiotherapy) will continue during the study. Fasting blood glucose will be measured at baseline and at one month following the interventions. Systolic and diastolic blood pressure (with participant sitting for at least 5 minutes prior to the measurement) values will be recoded as a mean of three consecutive readings at baseline and at one month following the interventions. Cross-sectional area (CSA) of tibial nerve at 3 cm proximal to cephalad edge of medial malleolus will also be measured prior to the first procedure and prior to the second procedure in participants with pain in distribution of the tibial nerve. Change in CSA (if any) will be correlated with analgesic response to perineural injections because decrease in CSA may indicate reduction in edema of the nerve.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date June 2019
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Pain in foot in neuro-anatomically congruent location following trauma (including surgery) for more than three months

2. Physician-reported DN4 scoring confirming neuropathic pain (score >3/10)

3. Average intensity of pain more than 3/10 on numerical rating score

4. Failed trial of appropriate doses of first line medications for neuropathic pain (anticonvulsants and/or antidepressants) for six weeks

Exclusion Criteria:

1. Age < 18 or Age > 80 years

2. Perineural or intra-articular steroid injections in the last 6 months

3. Allergy to local anesthetics or steroids

4. Ongoing litigation issues related to the patient's pain

5. Pregnancy

6. Coagulopathy or systemic infection

7. Peripheral neuropathy or myopathy, central neuropathic pain (e.g. post-stroke pain)

8. Infection in the ankle or foot

9. An unstable medical or psychiatric condition

10. Significant catastrophizing as indicated by pain catastrophizing scale (PCS) score equal to or more than 30/52.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bupivacaine

Depo-Medrol Injectable Product

Other:
Saline (Sodium Chloride) solution

Drug:
Lidocaine
Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections

Locations

Country Name City State
Canada Toronto Western Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of Numerical Rating Scores (NRS) (range 0-10) for foot and ankle pain One month after intervention
Secondary Measuring NRS (range 0-10) for foot and ankle pain Three months after intervention compared to pre-intervention
Secondary Measuring changes in the PCS (Pain Catastrophizing Scale) Questionnaire One month and three months after intervention compared to pre-intervention
Secondary Measuring changes in the Douleur Neuropathique (DN4) Questionnaire One month and three months after intervention compared to pre-intervention
Secondary Measuring change in the NPSI (Neuropathic Pain Symptom Inventory) Questionnaire One month and three months after intervention compared to pre-intervention
Secondary Measuring change in the Anxiety and Depression component scores on the Hospital Anxiety and Depression Scale (HADS) One month and three months after intervention compared to pre-intervention
Secondary Measuring change in Depression scores on the Patient Health Questionnaire (PHQ-9) One month and three months after intervention compared to pre-intervention
Secondary Measuring change in Brief Pain Inventory interference with activities (BPI-I) score One month and three months after intervention compared to pre-intervention
Secondary Measuring change in Short Form-12 (SF-12) score One month and three months after intervention compared to pre-intervention
Secondary Measuring change in Lower Extremity Function Score (LEFS) One month and three months after intervention compared to pre-intervention
Secondary Measuring change in pain (cold pain and heat pain) thresholds as determined by quantitative sensory testing (QST) One month and three months after intervention compared to pre-intervention
Secondary Measuring change in sensory (cold and hot detection) thresholds as determined by quantitative sensory testing (QST) One month and three months after intervention compared to pre-intervention
Secondary Measurement of the cross-sectional area of tibial nerve for neural edema between interventions One month and three months after intervention compared to pre-intervention
Secondary Measuring incidence of adverse effects Hyperglycemia (change in blood glucose levels) and hypertension (change in blood pressure levels)
Infections at the injection site, skin discolouration or atrophy at the injection site, fractures, and evidence of myopathy
One month and three months after intervention compared to pre-intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04066933 - Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M
Completed NCT01202227 - An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain Phase 3
Terminated NCT00964990 - A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) Phase 2
Completed NCT00922987 - Clinical Study With Lyrica In Patients Suffering From Epilepsy
Recruiting NCT00740571 - Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer Phase 3
Terminated NCT02747758 - Transcranial Direct Current Stimulation (tDCS) in Chronic Neuropathy N/A
Completed NCT05464199 - Home-based EEG Neurofeedback for Chronic Neuropathic Pain Phase 1
Completed NCT02490436 - Novel Treatment Option for Neuropathic Pain Phase 2
Completed NCT01974791 - GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain N/A
Completed NCT01279018 - Persistent Pain After Breast Cancer Treatment With Docetaxel N/A
Not yet recruiting NCT00944502 - To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins Phase 3
Completed NCT02957851 - EMONO for the Treatment of Peripheral Neuropathic Pain Phase 2
Completed NCT02180880 - Symptom Based Treatment of Neuropathic Pain Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00631943 - A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain Phase 3
Completed NCT03973983 - Comparison of Ultrasound-guided Transgluteal and Finger-guided Transvaginal Pudendal Nerve Block Techniques N/A
Terminated NCT03296111 - Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life
Not yet recruiting NCT06398847 - Virtual Reality (VR) Self-Hypnosis Software N/A
Terminated NCT02460107 - Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy Early Phase 1
Recruiting NCT01788410 - MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine